Skip to main content

Advertisement

Log in

Treatment of diffuse large B-cell lymphoma in the elderly: Strategies integrating oncogeriatric themes

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

With an increasingly aged population, many patients will present with diffuse large B-cell lymphoma in their 70s and 80s. Recently, several randomized studies have confirmed the benefit of rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and showed a substantial improvement in the outcome of fit elderly patients. This article reviews the efficacy and toxicity of the current treatment regimens applied for the treatment of diffuse large B-cell lymphoma in elderly patients and provides practical recommendations for the management of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ries LA, Melbert D, Krapcho M, et al.: SEER cancer statistics review, 1975–2004. Available at http://seer.cancer.gov/csr/1975_2004/results_merged/sect_19_nhl.pdf. Accessed August 2007.

  2. Effect of age on the characteristics and clinical behavior of non-Hodgkin’s lymphoma patients. The Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 1997, 8:973–978.

  3. Gatter KC, Warnke RA: Diffuse large B-cell lymphoma. In World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Edited by Jaffe ES, Harris NL, Stein H, et al. Lyon: IARC Press; 2001:171–174.

    Google Scholar 

  4. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937–1947.

    Article  PubMed  Google Scholar 

  5. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987–994.

  6. Pfreundschuh M, Schubert J, Ziepert M, et al.: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105–116.

    Article  PubMed  CAS  Google Scholar 

  7. Berrios-Rivera JP, Fang S, Cabanillas ME, et al.: Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol 2007, 30:163–171.

    Article  PubMed  Google Scholar 

  8. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, et al.: Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 2005, 41:1051–1057.

    Article  PubMed  Google Scholar 

  9. Bairey O, Benjamini O, Blickstein D, et al.: Non-Hodgkin’s lymphoma in patients 80 years of age or older. Ann Oncol 2006, 17:928–934.

    Article  PubMed  CAS  Google Scholar 

  10. Dixon DO, Neilan B, Jones SE, et al.: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986, 4:295–305.

    PubMed  CAS  Google Scholar 

  11. Sonneveld P, de Ridder M, van der Lelie H, et al.: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995, 13:2530–2539.

    PubMed  CAS  Google Scholar 

  12. Doorduijn JK, van der Holt B, van Imhoff GW, et al.: CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2003, 21:3041–3050.

    Article  PubMed  CAS  Google Scholar 

  13. Tirelli U, Errante D, Van Glabbeke M, et al.: CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin’s lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998, 16:27–34.

    PubMed  CAS  Google Scholar 

  14. Bastion Y, Blay JY, Divine M, et al.: Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment, and survival—a Groupe d’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J Clin Oncol 1997, 15:2945–2953.

    PubMed  CAS  Google Scholar 

  15. Bello C, Sotomayor EM: Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007, 2007:233–242.

    PubMed  Google Scholar 

  16. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235–242.

    Article  PubMed  CAS  Google Scholar 

  17. Feugier P, Van Hoof A, Sebban C, et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005, 23:4117–4126.

    Article  PubMed  CAS  Google Scholar 

  18. Habermann TM, Weller EA, Morrison VA, et al.: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121–3127.

    Article  PubMed  CAS  Google Scholar 

  19. Pfreundschuh M, Trumper L, Kloess M, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634–641.

    Article  PubMed  CAS  Google Scholar 

  20. Wunderlich A, Kloess M, Reiser M, et al.: Practicability and acute haematological toxicity of 2-and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol 2003, 14:881–893.

    Article  PubMed  CAS  Google Scholar 

  21. Sonneveld P, van Putten WL, Biesma D, et al.: Phase III trial of 2-weekly CHOP with rituximab for aggressive B-cell non-Hodgkin’s lymphoma in elderly patients [abstract]. Blood 2006, 108:210a.

    Article  Google Scholar 

  22. Ziepert M, Schmits R, Trumper L, et al.: Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin’s lymphoma. Ann Oncol 2008, 19:752–762.

    Article  PubMed  CAS  Google Scholar 

  23. Rueda A, Sabin P, Rifa J, et al.: R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematol Oncol 2008, 26:27–32.

    Article  PubMed  CAS  Google Scholar 

  24. Rigacci L, Nassi L, Alterini R, et al.: Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study. Acta Haematol 2006, 115:22–27.

    Article  PubMed  CAS  Google Scholar 

  25. Brusamolino E, Rusconi C, Montalbetti L, et al.: Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006, 91:496–502.

    PubMed  CAS  Google Scholar 

  26. Aapro MS, Cameron DA, Pettengell R, et al.: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006, 42:2433–2453.

    Article  PubMed  CAS  Google Scholar 

  27. Lyman GH, Delgado DJ: Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003, 98:2402–2409.

    Article  PubMed  Google Scholar 

  28. Shayne M, Culakova E, Poniewierski MS, et al.: Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007, 110:1611–1620.

    Article  PubMed  Google Scholar 

  29. Balducci L, Al-Halawani H, Charu V, et al.: Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007, 12:1416–1424.

    Article  PubMed  CAS  Google Scholar 

  30. Crawford J: Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia. Oncology (Williston Park) 2006, 20:22–28.

    Google Scholar 

  31. Lyman GH: Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005, 3:557–571.

    PubMed  Google Scholar 

  32. Smith TJ, Khatcheressian J, Lyman GH, et al.: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187–3205.

    Article  PubMed  CAS  Google Scholar 

  33. Burton C, Kaczmarski R, Jan-Mohamed R: Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003, 348:2690–2691; discussion 2690–2691.

    Article  PubMed  Google Scholar 

  34. Pfreundschuh DM, Zeynalova S, Poeschel V, et al.: Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): results of the DENSE-R-CHOP-14 trial if the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. Blood 2007, 110:789a.

    Article  Google Scholar 

  35. Kolstad A, Holte H, Fossa A, et al.: Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007, 92:139–140.

    Article  PubMed  CAS  Google Scholar 

  36. Wagner SA, Mehta AC, Laber DA: Rituximab-induced interstitial lung disease. Am J Hematol 2007, 82:916–919.

    Article  PubMed  CAS  Google Scholar 

  37. Halaas JL, Moskowitz CH, Horwitz S, et al.: R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma 2005, 46:541–547.

    Article  PubMed  CAS  Google Scholar 

  38. Osterborg A, Steegmann JL, Hellmann A, et al.: Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin’s lymphoma receiving combination chemotherapy. Br J Haematol 2007, 136:736–744.

    Article  PubMed  Google Scholar 

  39. Rizzo JD, Somerfield MR, Hagerty KL, et al.: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008, 111:25–41.

    Article  PubMed  CAS  Google Scholar 

  40. Bennett CL, Silver SM, Djulbegovic B, et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299:914–924.

    Article  PubMed  CAS  Google Scholar 

  41. Solomon D, Sue Brown A, Brummel-Smith K, et al.: Best paper of the 1980s: National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. 1988. J Am Geriatr Soc 2003, 51:1490–1494.

    Article  PubMed  Google Scholar 

  42. Wedding U, Rohrig B, Klippstein A, et al.: Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 2007, 133:945–950.

    Article  PubMed  Google Scholar 

  43. de Groot V, Beckerman H, Lankhorst GJ, et al.: How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003, 56:221–229.

    Article  PubMed  Google Scholar 

  44. Wedding U, Roehrig B, Klippstein A, et al.: Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale. Crit Rev Oncol Hematol 2007, 61:269–276.

    Article  PubMed  Google Scholar 

  45. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al.: A population-based study of severity of comorbidity among patients with non-Hodgkin’s lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005, 129:597–606.

    Article  PubMed  Google Scholar 

  46. Mori M, Kitamura K, Masuda M, et al.: Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin’s lymphoma. Int J Hematol 2005, 81:246–254.

    Article  PubMed  CAS  Google Scholar 

  47. Safra T, Muggia F, Jeffers S, et al.: Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000, 11:1029–1033.

    Article  PubMed  CAS  Google Scholar 

  48. Zaja F, Tomadini V, Zaccaria A, et al.: CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006, 47:2174–2180.

    Article  PubMed  CAS  Google Scholar 

  49. Sharpe M, Easthope SE, Keating GM, et al.: Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi’s sarcoma. Drugs 2002, 62:2089–2126.

    Article  PubMed  CAS  Google Scholar 

  50. Wildiers H, Highley MS, de Bruijn EA, et al.: Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003, 42:1213–1242.

    Article  PubMed  CAS  Google Scholar 

  51. Balducci L, Extermann M: Management of cancer in the older person: a practical approach. Oncologist 2000, 5:224–237.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pieternella J. Lugtenburg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lugtenburg, P.J., Sonneveld, P. Treatment of diffuse large B-cell lymphoma in the elderly: Strategies integrating oncogeriatric themes. Curr Oncol Rep 10, 412–419 (2008). https://doi.org/10.1007/s11912-008-0063-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-008-0063-2

Keywords

Navigation